Rapha Capital Management is a venture capital firm in Miami that focuses on medicine, healthcare and technology. Founded in Miami, Florida, United States by Kevin Slawin, it invests in series C and convertible notes. Its portfolio companies include Poseida Therapeutics, and AsclepiX Therapeutics. Poseida Therapeutics utilizes best-in-class genome engineering capabilities to develop targeted lifesaving therapeutics. AsclepiX Therapeutics is a biotech company that develops novel therapeutics to revolutionize the treatment of retinal diseases and cancer. As of March 2020, Rapha Capital Management has made two investments. Their most recent investment was on April 22, 2019, when Poseida Therapeutics raised $142M.
I, LP, is solely focused on investment in early-stage life science companies. The fund will focus on securing the investment lead, typically at Series A or just before, in target companies.
Kevin Slawin, MD, the Founder and Managing Partner of Rapha Capital Management, LLC is an oncologic and robotic surgeon, biotech consultant, investor, and founder focusing on disruptive technologies in oncology, T cells and immunotherapy, as well as other breakthrough healthcare technologies.
Documentaries, videos and podcasts